Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | EED | O75530 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL14677992 | 0.98 | HTR2C (0.41) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL30000911 | 0.79 | HTR2C (0.42) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL9411933 | 0.79 | HTR2C (0.40) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL5743895 | 0.76 | HTR2C (0.40) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL25240958 | 0.66 | HTR1D (0.41) | DRD3 | |
| SCHEMBL4429415 | 0.65 | PAX8 (0.48) | HTR2CHTR2AHTR2BNFKB1MAOA | |
| SCHEMBL13983903 | 0.63 | HTR2C (0.66) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL3633037 | 0.62 | HTR2A (0.46) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL1555111 | 0.61 | HTR2A (0.45) | HTR2CHTR2AHTR2BHTR1ADRD3 | |
| SCHEMBL9411925 | 0.61 | HTR2C (0.57) | HTR2CHTR2AHTR2BHTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315956-A1 | SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF | NATIONWIDE CHILDREN'S HOSPITAL (US) | 2014-10-23 | — | — | US | disclosed |
| WO-2013019690-A1 | SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF | THE OHIO STATE UNIVERSITY (US) | 2013-02-07 | — | — | WO | disclosed |
| JP-2002212186-A | METHOD FOR PRODUCING MADINDOLINE A AND B | JAPAN SCIENCE & TECHNOLOGY CORP | 2002-07-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315956-A1 | SMALL MOLECULE INHIBITORS OF IL-6 AND USES THEREOF | IL6, STAT3, JAK2 | HTR2C 781/4885HTR2A 1015/4885HTR2B 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.